1. Market Research
  2. > Pharmaceutical Market Trends
  3. > India Pharmaceuticals and Healthcare Report Q3 2016

India Pharmaceuticals and Healthcare Report Q3 2016

  • May 2016
  • -
  • Business Monitor International
  • -
  • 118 pages

Includes 3 FREE quarterly updates

BMI View: The tough operating environment for multinational drugmakers in India will see littleimprovement over the medium term. Designated as a 'Priority Watch List Country' for PhRMA's Special301 submission for 2016, the issues raised largely mirrored those touched upon in the 2015 submission,such as low levels of intellectual property and challenges in market access. As a result of these factors,innovative firms will adopt a cautious approach to India, which remains attractive due to its large medicinemarket size.Headline Expenditure ProjectionsPharmaceuticals: INR1,065bn (USD16bn) in 2015 to INR1,191bn (17bn) by 2016; +11.8% in localcurrency terms and 5.1% in US dollar terms. Forecast unchanged from last quarter.Healthcare: INR6,695bn (USD104bn) in 2015 to INR7,561bn (USD110bn) by 2016; +12.9% in localcurrency terms and 6.2% in US dollar terms. Forecast revised upwards from last quarter.

Table Of Contents

India Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (India 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (India 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (India 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (India 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (India 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (India 2012-2020) 21
Patented Drug Market Forecast 22
Table: Selected Patent Developments Affecting Drugmakers 23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (India 2012-2020) 25
Generic Drug Market Forecast 26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (India 2012-2020) 27
OTC Medicine Market Forecast 28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (India 2012-2020) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (India 2014-2020) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (India 2014-2020) 32
Industry Risk/Reward Index 33
Asia Pacific Risk/Reward Index - Q3 2016 33
India Risk/Reward Index 39
Rewards 39
Risks 39
Regulatory Review 41
Intellectual Property Issues 45
Table: History Of The Indian Patent System 46
Table: Special 301 Submission: Issues Raised For India 47
Table: A Series Of Setbacks For Innovative Pharmaceutical Firms 47
Pricing Regime 51
Market Overview 56
Healthcare Sector 56
Table: Healthcare Resources (India 2010-2015) 59
Table: Healthcare Personnel (India 2010-2015) 59
Table: Healthcare Activity (India 2010-2015) 60
Clinical Trials 62
Epidemiology 64
Table: Estimated Number Of New Cases Of Cancer In India 66
Competitive Landscape 67
Research-Based Industry 67
Table: Ordinary Members Of OPPI 67
Table: Multinational Market Activity 68
Pharmaceutical Distribution 70
Pharmaceutical Retail Sector 70
Company Profile 72
Aurobindo Pharmaceutical 72
Cipla 75
Dr Reddy's Laboratories 79
GlaxoSmithKline 83
Merck and Co 88
Novartis 91
Pfizer 95
Sanofi India 100
Sun Pharmaceutical 104
Demographic Forecast 107
Table: Population Headline Indicators (India 1990-2025) 108
Table: Key Population Ratios (India 1990-2025) 108
Table: Urban/Rural Population and Life Expectancy (India 1990-2025) 109
Table: Population By Age Group (India 1990-2025) 109
Table: Population By Age Group % (India 1990-2025) 110
Glossary 112
Methodology 114
Pharmaceutical Expenditure Forecast Model 114
Healthcare Expenditure Forecast Model 114
Notes On Methodology 115
Risk/Reward Index Methodology 116
Index Overview 117
Table: Pharmaceutical Risk/Reward Index Indicators 117
Indicator Weightings 118

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes

  • $ 6 995
  • Industry report
  • February 2016
  • by GBI Research

Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes Summary The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 ...

Opportunity in the Indian Pharmaceutical Market - 2016; Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast

Opportunity in the Indian Pharmaceutical Market - 2016; Market size, Market share, Market landscape, Market trend analysis, Growth drivers, Future opportunity, Future forecast

  • $ 5 750
  • Industry report
  • April 2016
  • by Feedback Business Consulting

This report provides an insight into the Indian Pharmaceutical current market scenario, structure and practices. In depth market scenario includes; - Current market size estimates, including domestic market, ...

Omega 3 PUFA Market: Type (DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), ALA (Alpha-linoleic acid)) Source (Marine, Plant) Form (Oils, Capsules, Powder) Application (Dietary Supplements, Pharmaceuticals, Infant Foods, F&B)-Forecast(2015-2020)

Omega 3 PUFA Market: Type (DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), ALA (Alpha-linoleic acid)) Source (Marine, Plant) Form (Oils, Capsules, Powder) Application (Dietary Supplements, Pharmaceuticals, Infant Foods, F&B)-Forecast(2015-2020)

  • $ 5 250
  • Industry report
  • February 2016
  • by Industry ARC

Omega-3 fatty acids are polyunsaturated fatty acids which have potential health benefits and are essential for increasing metabolic rate. Omega-3 PUFA ingredients are used to manufacture products that ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.